0001213900-26-109190.txt : 20261014 0001213900-26-109190.hdr.sgml : 20261014 20261013205037 ACCESSION NUMBER: 0001213900-26-109190 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20261014 DATE AS OF CHANGE: 20261013 EFFECTIVENESS DATE: 20261014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tempest Therapeutics, Inc. CENTRAL INDEX KEY: 0001544227 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 451472564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-601073 FILM NUMBER: 261458100 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 415-798-8589 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Millendo Therapeutics, Inc. DATE OF NAME CHANGE: 20181207 FORMER COMPANY: FORMER CONFORMED NAME: OvaScience, Inc. DATE OF NAME CHANGE: 20120308 D 1 primary_doc.xml X0708 D LIVE 0001544227 Tempest Therapeutics, Inc. 2000 SIERRA POINT PARKWAY, SUITE 400 BRISBANE CA CALIFORNIA 94005 415-798-8589 DELAWARE None Millendo Therapeutics, Inc. OvaScience, Inc. Corporation true Matthew Angel Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Executive Officer Director President and Chief Executive Officer Constance Ames Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Executive Officer Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary John David Yee Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director William Drake Richey Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director Nancy Freda-Smith Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director John Wilbert Frederick Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director Biotechnology Decline to Disclose 06b false 2026-09-15 true true true true Pre-funded warrants and Series C and Series D Common Stock Purchase Warrants, including underlying shares of common stock. false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 NY NEW YORK false 7500000 7500000 0 Offering of 3,105,591 pre-funded warrants and accompanying 3,105,591 Series C and 3,105,591 Series D warrants, including the common stock underlying such warrants at combined exercise price of $0.804. Total offering amount excludes PA warrants (Item 15). false 1 225000 0 Includes a cash placement fee equal to 7.0% of the gross proceeds of the offering, reimbursement of $50,000 legal fees and warrants, exercisable upon stockholder approval, to purchase 217,391 common stock at an exercise price of $1.0063 per share. 0 false Tempest Therapeutics, Inc. /s/ Matthew Angel Matthew Angel President and Chief Executive Officer 2026-10-13